- Home
- RLGT vs XFOR Comparison
RLGT vs XFOR Comparison
Compare RLGT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLGT | XFOR |
|---|---|---|
| Founded | 2001 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Oil Refining/Marketing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.1M | 407.5M |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLGT | XFOR |
|---|---|---|
| Price | $8.97 | $4.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $8.00 | ★ $9.00 |
| AVG Volume (30 Days) | 132.3K | ★ 386.6K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.75 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $902,696,000.00 | N/A |
| Revenue This Year | $2.13 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | $39.09 | ★ N/A |
| Revenue Growth | ★ 12.49 | N/A |
| 52 Week Low | $5.78 | $1.35 |
| 52 Week High | $9.45 | $4.83 |
Technical Indicators
Market Signals| Indicator | RLGT | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 57.01 |
| Support Level | $5.86 | $3.58 |
| Resistance Level | $9.45 | $4.54 |
| Average True Range (ATR) | 0.30 | 0.21 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 54.72 | 83.58 |
Price Performance
Historical ComparisonAbout RLGT Radiant Logistics Inc.
Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.